← Leaderboards
Sunil S. Badve
Intica Biomedical, Inc.
$2,522,361
Attributed
$5,191,484
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,191,484 · 5
By mechanism
R01$3,946,338 · 2
R33$440,287 · 1
R41$417,014 · 1
R21$387,845 · 1
Top collaborators
- Michael Gerdes3 shared
- Soumya Ghose2 shared
- Fiona Ginty2 shared
- Christopher Horvath2 shared
- Anant Madabhushi2 shared
- Brian Michael Davis1 shared
- Yesim Gokmen Polar1 shared
Most similar at Intica Biomedical, Inc.
Same institution · by research overlap
- Christopher Horvath$408,507
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant Breast NeoplasmRecurrenceRegimenUniversitiesOperative Surgical ProceduresMalignant NeoplasmsBreastChemotherapyCohortBaseWomanIncidenceEventCellsBiopsyMolecularIpsilateralLesionCarcinomaIndianaHormone TherapyBreast Cancer PatientAdverse Event
Grant awards (12)
Early prediction of lethal phenotypes in triple negative breast cancer using multiscale, multi-modality platforms$605,142
R01 · FY2025 · CA · contact PI
A Novel Multi-analyte Approach to Democratize Cancer Biobanking$440,287
R33 · FY2025 · CA
Early prediction of lethal phenotypes in triple negative breast cancer using multiscale, multi-modality platforms$614,757
R01 · FY2024 · CA · contact PI
(PQC3) Ethnicity-determined immune response and DCIS outcome$479,117
R01 · FY2019 · CA · contact PI
(PQC3) Ethnicity-determined immune response and DCIS outcome$179,518
R01 · FY2018 · CA · contact PI
(PQC3) Ethnicity-determined immune response and DCIS outcome$675,664
R01 · FY2017 · CA · contact PI
(PQC3) Ethnicity-determined immune response and DCIS outcome$684,967
R01 · FY2016 · CA · contact PI
Computerized morphologic-molecular predictor of progression in DCIS$201,504
R21 · FY2016 · CA
(PQC3) Ethnicity-determined immune response and DCIS outcome$707,173
R01 · FY2015 · CA · contact PI
Computerized morphologic-molecular predictor of progression in DCIS$186,341
R21 · FY2015 · CA
Evaluation of In Vitro Companion Diagnostic Monoclonal Antibodies for Use in a St$149,799
R41 · FY2013 · CA
Evaluation of In Vitro Companion Diagnostic Monoclonal Antibodies for Use in a St$267,215
R41 · FY2012 · CA